Cargando…

Anchor-based classification and type-C inhibitors for tyrosine kinases

Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Kai-Cheng, Sung, Tzu-Ying, Lin, Chih-Ta, Chiu, Yi-Yuan, Hsu, John T.-A., Hung, Hui-Chen, Sun, Chung-Ming, Barve, Indrajeet, Chen, Wen-Liang, Huang, Wen-Chien, Huang, Chin-Ting, Chen, Chun-Hwa, Yang, Jinn-Moon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468516/
https://www.ncbi.nlm.nih.gov/pubmed/26077136
http://dx.doi.org/10.1038/srep10938
_version_ 1782376517482840064
author Hsu, Kai-Cheng
Sung, Tzu-Ying
Lin, Chih-Ta
Chiu, Yi-Yuan
Hsu, John T.-A.
Hung, Hui-Chen
Sun, Chung-Ming
Barve, Indrajeet
Chen, Wen-Liang
Huang, Wen-Chien
Huang, Chin-Ting
Chen, Chun-Hwa
Yang, Jinn-Moon
author_facet Hsu, Kai-Cheng
Sung, Tzu-Ying
Lin, Chih-Ta
Chiu, Yi-Yuan
Hsu, John T.-A.
Hung, Hui-Chen
Sun, Chung-Ming
Barve, Indrajeet
Chen, Wen-Liang
Huang, Wen-Chien
Huang, Chin-Ting
Chen, Chun-Hwa
Yang, Jinn-Moon
author_sort Hsu, Kai-Cheng
collection PubMed
description Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in the C-terminal hinge region by docking 4,680 kinase inhibitors into 51 protein kinases, and this finding provides an opportunity for the development of kinase inhibitors with high selectivity and anti-drug resistance. We present an anchor-based classification for tyrosine kinases and discover two type-C inhibitors, namely rosmarinic acid (RA) and EGCG, which occupy two and one specific anchors, respectively, by screening 118,759 natural compounds. Our profiling reveals that RA and EGCG selectively inhibit 3% (EGFR and SYK) and 14% of 64 kinases, respectively. According to the guide of our anchor model, we synthesized three RA derivatives with better potency. These type-C inhibitors are able to maintain activities for drug-resistant EGFR and decrease the invasion ability of breast cancer cells. Our results show that the type-C inhibitors occupying a new pocket are promising for cancer treatments due to their kinase selectivity and anti-drug resistance.
format Online
Article
Text
id pubmed-4468516
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44685162015-06-18 Anchor-based classification and type-C inhibitors for tyrosine kinases Hsu, Kai-Cheng Sung, Tzu-Ying Lin, Chih-Ta Chiu, Yi-Yuan Hsu, John T.-A. Hung, Hui-Chen Sun, Chung-Ming Barve, Indrajeet Chen, Wen-Liang Huang, Wen-Chien Huang, Chin-Ting Chen, Chun-Hwa Yang, Jinn-Moon Sci Rep Article Tyrosine kinases regulate various biological processes and are drug targets for cancers. At present, the design of selective and anti-resistant inhibitors of kinases is an emergent task. Here, we inferred specific site-moiety maps containing two specific anchors to uncover a new binding pocket in the C-terminal hinge region by docking 4,680 kinase inhibitors into 51 protein kinases, and this finding provides an opportunity for the development of kinase inhibitors with high selectivity and anti-drug resistance. We present an anchor-based classification for tyrosine kinases and discover two type-C inhibitors, namely rosmarinic acid (RA) and EGCG, which occupy two and one specific anchors, respectively, by screening 118,759 natural compounds. Our profiling reveals that RA and EGCG selectively inhibit 3% (EGFR and SYK) and 14% of 64 kinases, respectively. According to the guide of our anchor model, we synthesized three RA derivatives with better potency. These type-C inhibitors are able to maintain activities for drug-resistant EGFR and decrease the invasion ability of breast cancer cells. Our results show that the type-C inhibitors occupying a new pocket are promising for cancer treatments due to their kinase selectivity and anti-drug resistance. Nature Publishing Group 2015-06-16 /pmc/articles/PMC4468516/ /pubmed/26077136 http://dx.doi.org/10.1038/srep10938 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Hsu, Kai-Cheng
Sung, Tzu-Ying
Lin, Chih-Ta
Chiu, Yi-Yuan
Hsu, John T.-A.
Hung, Hui-Chen
Sun, Chung-Ming
Barve, Indrajeet
Chen, Wen-Liang
Huang, Wen-Chien
Huang, Chin-Ting
Chen, Chun-Hwa
Yang, Jinn-Moon
Anchor-based classification and type-C inhibitors for tyrosine kinases
title Anchor-based classification and type-C inhibitors for tyrosine kinases
title_full Anchor-based classification and type-C inhibitors for tyrosine kinases
title_fullStr Anchor-based classification and type-C inhibitors for tyrosine kinases
title_full_unstemmed Anchor-based classification and type-C inhibitors for tyrosine kinases
title_short Anchor-based classification and type-C inhibitors for tyrosine kinases
title_sort anchor-based classification and type-c inhibitors for tyrosine kinases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468516/
https://www.ncbi.nlm.nih.gov/pubmed/26077136
http://dx.doi.org/10.1038/srep10938
work_keys_str_mv AT hsukaicheng anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT sungtzuying anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT linchihta anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT chiuyiyuan anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT hsujohnta anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT hunghuichen anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT sunchungming anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT barveindrajeet anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT chenwenliang anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT huangwenchien anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT huangchinting anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT chenchunhwa anchorbasedclassificationandtypecinhibitorsfortyrosinekinases
AT yangjinnmoon anchorbasedclassificationandtypecinhibitorsfortyrosinekinases